Risk Factors Associated with Reoperation for Bleeding following Liver Transplantation

Table 1

Baseline demographics.

Variable	Reoperation for bleeding	Control group	value
Group
Age (years)	51.7 ± 11.9	53.5 ± 9.7	0.16
Male (%)	54.5	63.4	0.08
Race
Caucasian %	81.2	85.9	0.43
African-American %	14.9	10.8
BMI	29.6 ± 6.3	29.0 ± 6.4	0.43
Etiology of liver disease (%)
Hepatitis C	44.6	36.4	0.11
NASH/cryptogenic	15.8	20.6	0.26
Laennec’s	9.0	12.7	0.28
Cholestatic (PBC, PSC)	9.9	11.9	0.55
Other^a	8.9	9.0	0.98
MELD Score	23.8 ± 8.1	20.4 ± 7.9	<0.001
ICU prior to liver transplant (%)	23.2	12.9	0.005
Comorbidities
Dyslipidemia	12.9	13.6	0.85
Diabetes	21.8	26.3	0.33
CAD	5.0	3.5	0.47
CRI	10.9	7.5	0.24
Hypertension	51.5	47.3	0.42
Baseline lab values
Platelet count (×10^9/L)	88.8	79.9	0.14
Hematocrit	26.0 ± 8.0	25.8 ± 8.9	0.80
INR	2.1 ± 0.9	1.9 ± 0.9	0.04
Split liver transplant (%)	1.0	0.25	0.30

Data presented as percent or mean ± standard deviation.
^aOther diagnoses include autoimmune hepatitis, alpha 1 antitrypsin deficiency, hemochromatosis, fulminant liver failure, Budd-Chiari syndrome, Wilson’s disease, polycystic liver disease, nonhepatocellular carcinoma neoplastic disease, sarcoidosis, secondary biliary cirrhosis, Caroli’s disease, and cystinosis.
NASH: nonalcoholic steatohepatitis; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis; MELD: Model for End-Stage Liver Disease; BMI: body mass index; CAD: coronary artery disease; CRI: chronic renal insufficiency; INR: international normalized ratio.